Log in to your Inderes Free account to see all free content on this page.
Dicot Pharma
0.30 SEK
-19.52 %
Less than 1K followers
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-19.52 %
-21.90 %
+7.49 %
-0.91 %
+4.90 %
-11.57 %
+107.84 %
-53.89 %
-88.10 %
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization. The company is based in Uppsala.
Read moreMarket cap
611.24M SEK
Turnover
17.28M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
30.4.
2026
Interim report Q1'26
6.5.
2026
General meeting '26
20.8.
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Pharma publishes its Annual Report for 2025
NOTICE OF ANNUAL GENERAL MEETING IN DICOT PHARMA AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio